Oral cavity composition containing hinokitiol

Abstract

To provide a composition for oral use which contains hinokitiol or a salt thereof but still secures temporal stability of hinokitiol in a dosage form.SOLUTION: The invention relates to a composition for oral use which contains hinokitiol. The composition for oral use secures temporal stability of hinokitiol in a dosage form by using a water-soluble pyrophosphate, and achieves a synergy effect in preventing, mitigating and treating an oral disease.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to an oral composition containing hinokitiol.

[0002] This application claims priority based on Korean Patent Application No. 10-2021-0085153, filed on June 29, 2021, and the entire contents disclosed in the specification and drawings of that application are incorporated herein by reference. [Background technology]

[0003] As the concept of dental health expands to include social life, interest in oral health is increasing, and interest is growing not only in the prevention and treatment of oral diseases but also in bad breath, which can impair interpersonal relationships in social life.

[0004] Tooth tissue is composed of enamel, cementum, and dentin. The surface of the tooth that is exposed to the outside is covered with enamel, and the surface of the root part located within the alveolar bone is covered with cementum, and dentin exists within these. Dentin contains tiny tubes called dentinal tubules that are distributed throughout the dentin.

[0005] Among oral diseases, dental caries and periodontal disease are known to induce various clinical symptoms such as pain, impaired chewing function, destruction of periodontal tissues, and bad breath, and are known to be major factors leading to tooth loss. In fact, the causative factors of dental caries are increasing due to changes in dietary habits.

[0006] As a method for inhibiting the growth of oral pathogenic bacteria that inhabit the bacterial film on the tooth surface and cause dental caries, periodontal disease, and bad breath, various types of antibacterial preparations, including antibiotics that have bactericidal and bacteriostatic effects against these bacteria, have been developed as agents for inhibiting and treating dental caries, periodontal disease, and pulp and periapical infections.

[0007] Hinokitiol is known to be effective in preventing and treating periodontal disease due to its excellent antibacterial and anti-inflammatory properties, and to have an astringent effect on wounds and prevent bad breath. However, hinokitiol is chemically unstable, and therefore does not exhibit sufficient efficacy and activity when incorporated into oral compositions. Its storage stability is also reduced, resulting in a very low residual rate of hinokitiol over time when stored for a long period of time.

[0008] Therefore, there is a need to develop an oral composition containing stabilized hinokitiol that suppresses the reactivity of hinokitiol within the oral composition, improves stability, and maintains activity when applied to the oral cavity.

[0009] Numerous documents are referenced and cited throughout this specification, the disclosures of which are hereby incorporated by reference in their entireties into this specification to more clearly describe the state of the art to which this invention pertains and the content of the present invention. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] Korean Patent Registration No. 10-2208440 Summary of the Invention [Problem to be solved by the invention]

[0011] The present invention was completed by confirming that when a water-soluble pyrophosphate salt is added to an oral composition containing hinokitiol, the stability of hinokitiol within the dosage form over time can be ensured and a synergistic effect can be achieved in the efficacy for the oral cavity.

[0012] Therefore, an object of the present invention is to provide an oral composition which contains hinokitiol or a salt thereof and which ensures the stability of hinokitiol over time within the dosage form.

[0013] Another object of the present invention is to provide an oral composition that ensures the stability of hinokitiol in the dosage form over time and can realize a synergistic effect in efficacy for the oral cavity.

[0014] A further object of the present invention is to provide an oral product containing the oral composition containing hinokitiol.

[0015] Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention and the claims. [Means for solving the problem]

[0016] One aspect of the present invention is to provide an oral composition comprising (i) hinokitiol or a salt thereof and (ii) a water-soluble pyrophosphate salt.

[0017] In the present invention, the composition may be for preventing, alleviating or treating oral diseases.

[0018] In the present invention, the oral disease is a comprehensive concept including, but not limited to, bad breath, sensitive teeth, caries, gingivitis, periodontitis, oral mucosal ulcers, and periapical diseases.

[0019] As used herein, the term "prevention" refers to any action that suppresses or delays a disease using the oral composition, and the term "treatment" refers to any action that alleviates or completely cures the symptoms of a disease using the oral composition.

[0020] Furthermore, the term "alleviation" as used in this specification means that the symptoms of the oral diseases mentioned above are reduced or alleviated, and can be understood as a broad concept including improvement, prevention, treatment, etc.

[0021] Furthermore, the term "improvement" used in this specification can be understood as a broad concept meaning treating an oral disease or the like to restore symptoms to nearly their original state.

[0022] The term "bad breath" as used herein refers to, but is not limited to, acquired systemic diseases, or substances that are produced by the breakdown of proteins in saliva, food residues, etc. by microorganisms in the oral cavity, which then produce substances that cause a malodor. Oral microorganisms that are the primary cause of bad breath include, but are not limited to, Streptococcus, Porphyromonas, Actinomyces, and Actinobacillus.

[0023] As used herein, the term "dental caries" refers to, but is not limited to, tooth decay caused by bacteria in the oral cavity. For example, dental caries can be caused by plaque, a biofilm formed on the surface of teeth. The oral bacteria can be Streptococcus, Porphyromonas, etc.

[0024] The terms "gingivitis" and "periodontitis" as used herein may refer to, but are not limited to, oral diseases in which bacteria such as Streptococcus and Porphyromonas present in subgingival plaque infect the soft tissues of the gums when suitable growth conditions are created, leading to periodontal diseases such as gingival salts or periodontitis, causing inflammation of the gums.

[0025] The term "oral mucosal ulcer" as used herein, also known as stomatitis, refers to a disease in which inflammation occurs in the oral mucosa (tongue, gums, lips, inside of the cheek, etc.) due to infection with oral bacteria, viruses, fungi, etc., but is not limited to these, and the bacteria may be bacteria of the genus Streptococcus, Porphyromonas, etc.

[0026] The term "periapical disease" as used herein may refer to inflammation occurring at the apex, which is the end of the root of a tooth, but is not limited thereto. Examples of periapical disease include periapical cysts, periapical abscesses, and periapical osteosarcomas, which may be caused by bacteria such as Streptococcus and Porphyromonas.

[0027] As used herein, the term "sensitive teeth" refers to any condition in which teeth are sensitive to external stimuli, independent of caries or other pathological causes, and cause temporary or persistent pain. The external stimuli typically refer to temperature stimuli, and although cold stimuli are common, hot stimuli can also cause pain. In addition to temperature stimuli, tooth dryness, contact with external substances, and osmotic pressure from sweet or sour foods can also cause pain. Sensitivity can occur throughout the entire tooth or can be limited to specific areas, such as the upper or lower jaw, right or left side, and can be associated with dentin hyperesthesia, caries, or pulpitis.

[0028] The cause of such tooth sensitivity is the exposure of the entrances of the dentinal tubules.

[0029] When the enamel or cementum is destroyed and the entrance of the dentinal tubule is exposed to the outside, stimuli are transmitted to the dental pulp side by the cell processes, nerves and fluid in the dentinal tubule, and pain can be felt.

[0030] The inventors of the present invention have confirmed that an oral composition comprising (i) hinokitiol or its salt and (ii) a water-soluble pyrophosphate salt can ensure the stability of hinokitiol over time within the dosage form and can also achieve synergistic effects in the prevention, alleviation, and treatment of the aforementioned oral diseases.

[0031] The hinokitiol or salt thereof of the present invention may be hinokitiol itself or a salt formed with an acid or a base.

[0032] Salts formed with acids are useful as acid addition salts formed with free acids, which can be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, and non-toxic organic acids such as aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates and alkanedioates, aromatic acids, aliphatic and aromatic sulfonic acids. Such non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate. Examples of suitable sulfonates include, but are not limited to, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, or mandelate.

[0033] Hinokitiol metal salts formed using a base may also be included. The alkali metal or alkaline earth metal salts can be obtained, for example, by dissolving a hinokitiol compound in a solution of an excess amount of alkali metal hydroxide or alkaline earth metal hydroxide, filtering off the undissolved compound salts, and evaporating and drying the filtrate.

[0034] The hinokitiol or a salt thereof may be contained in an amount of 0.001 to 1% by weight, preferably 0.005 to 0.5% by weight, more preferably 0.01 to 0.2% by weight, and even more preferably 0.01 to 0.1% by weight, based on the total weight of the composition.

[0035] The water-soluble pyrophosphate salt contained in the oral composition of the present invention is at least one selected from the group consisting of alkali metal pyrophosphate salts and alkaline earth metal pyrophosphate salts, specifically, tetrasodium pyrophosphate (TSPP; Na4P2O7), potassium pyrophosphate (K4P2O7), sodium acid pyrophosphate (SAPP; Na2H2P2O7), dipotassium dihydrogen pyrophosphate (K2H2P2O7), and disodium dipotassium pyrophosphate (Na2K2P2O7).

[0036] The water-soluble pyrophosphate may be contained in an amount of 0.01 to 10% by weight, preferably 0.05 to 8% by weight, more preferably 0.1 to 5% by weight, based on the total weight of the composition.

[0037] By containing the water-soluble pyrophosphate, the oral composition of the present invention has a stability of hinokitiol in the dosage form (storage at 50°C for 1 month) that is at least 1.5 times, at least 2 times, at least 3 times, at least 4 times, or at least 5 times higher than a composition that does not contain it.

[0038] In one embodiment, the oral composition of the present invention may be free of ingredients such as chelating agents such as EDTA, carboxylic acid amphoteric surfactants, and / or ethyl alcohol.

[0039] Although EDTA is a substance harmful to the human body, and carboxylic acid-type amphoteric surfactants and ethyl alcohol are irritating to infant mucous membranes, these components have been included in conventional oral compositions to ensure the stability of hinokitiol over time.The composition of the present invention uses a water-soluble pyrophosphate salt, which ensures much higher stability of hinokitiol over time without including the above-mentioned harmful or irritating components to infant mucous membranes.

[0040] The present inventors have confirmed that the oral composition of the present invention has an antibacterial effect against one or more microorganisms selected from the group consisting of microorganisms of the genus Streptococcus and Porphyromonas. More specifically, the oral composition of the present invention has an excellent antibacterial effect against one or more bacteria selected from the group consisting of Streptococcus mutans, Streptococcus sanguis, Streptococcus sanguinis, Streptococcus salivarius subsp. thermophilus, and Porphyromonas gingivalis, and is therefore highly effective in preventing and treating oral diseases.

[0041] More preferably, the oral composition of the present invention has excellent antibacterial effect against Streptococcus mutans and / or Porphyromonas gingivalis bacteria.

[0042] Furthermore, by containing the water-soluble pyrophosphate, the oral composition of the present invention may have an antibacterial effect against oral pathogenic strains (Streptococcus mutans and / or Porphyromonas gingivalis) that is at least 2 times, at least 5 times, at least 10 times, at least 50 times, at least 100 times, at least 500 times, at least 1,000 times, at least 5,000 times, or at least 10,000 times higher than a composition that does not contain the water-soluble pyrophosphate.

[0043] In addition to the above-mentioned ingredients, the oral composition of the present invention may further contain ingredients that are commonly used depending on its dosage form and intended use, such as humectants, abrasives, medicinal agents, sweeteners, pH adjusters, preservatives, binders, flavorings, and foaming agents.

[0044] As the humectant, a component selected from the group consisting of concentrated glycerin, glycerin, sorbitol aqueous solution, amorphous sorbitol aqueous solution, polyethylene glycols, and propylene glycol can be used alone or in combination, and the amount used can be 1 to 70% by weight based on the total weight of the oral composition.

[0045] The abrasive may be one selected from the group consisting of precipitated silica, silica gel, zirconium silicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, hydrous alumina, light calcium carbonate, heavy calcium carbonate, calcium pyrophosphate, insoluble metaphosphate, and aluminum silicate. The amount of such an abrasive used may typically be 1 to 60 wt. % of the total weight of the oral composition. Additives used in small amounts may include commonly used ingredients such as sweeteners, pH adjusters, preservatives, colorants, and binders.

[0046] The medicinal agents include sodium fluoride, sodium monofluorophosphate, stannous fluoride, chlorhexidine, allantoin chlorohydroxyaluminate, aminocaproic acid, zinc chloride, pyridoxine hydrochloride, tocopherol acetate, enzymes, etc., which may be used alone or in combination of two or more.

[0047] Examples of binders that can be used include sodium carboxymethylcellulose, carbomer, carrageenan, xanthan gum, and alginates, and examples of foaming agents that can be used include anionic and nonionic surfactants such as sodium alkyl sulfate, sodium lauryl sulfate, sucrose fatty acid esters, and sorbitan fatty acid esters, either alone or in combination. The amount of such binders used is usually 0.1 to 3 wt. % and preferably 0.5 to 2 wt. % of the total weight of the oral composition.

[0048] As the sweetener, saccharin, xylitol, erythritol, aspartame, etc. can be used, and the amount of such a sweetener used can usually be 0.05 to 2% by weight based on the total weight of the oral composition.

[0049] As the pH adjuster, sodium phosphate, disodium phosphate, citric acid, triethanolamine, etc. may be used.

[0050] Preservatives that can be used include benzoic acid, methylparaben, propylparaben, sodium benzoate, etc. Flavoring agents that can be used include peppermint oil, spearmint oil, menthol, etc., and enzymes such as dextranase can be used as other additives.

[0051] Examples of foaming agents that can be used include anionic surfactants such as sodium lauryl sulfate, nonionic surfactants such as polyoxyethylene-polyoxypropylene copolymers (poloxamers), polyoxyethylene hydrogenated castor oil, and polyoxyethylene sorbitan fatty acid esters. The amount of such foaming agents used is usually 0.5 to 5% by weight, preferably 0.5 to 3.5% by weight, based on the total weight of the oral composition.

[0052] In addition, it may contain a residual amount of water.

[0053] According to yet another embodiment of the present invention, the present invention provides an oral product comprising the composition.

[0054] The oral composition according to the present invention may be contained in any product typically manufactured and sold for oral health, and the type of oral product to which it may be applied is not limited. For example, the oral product may include, but is not limited to, toothpaste, mouth spray, mouthwash, oral ointment, mouthwash, gargle, gum, etc. The oral product of the present invention may be in the form of, but is not limited to, a liquid, solid, suspension, gel, or aerosol.

[0055] Preferably, all of the components described in the present invention do not exceed the maximum use values ​​specified in the relevant laws, regulations, and standards of Korea, China, the United States, Europe, Japan, etc. (e.g., Regulations Concerning Cosmetic Safety Standards (Korea), Cosmetic Safety Technical Standards (China)). That is, preferably, the oral composition or personal care composition according to the present invention contains the components according to the present invention in amounts within the limits permitted by the relevant laws, regulations, and standards of each country. [Effects of the Invention]

[0056] The oral composition of the present invention uses a water-soluble pyrophosphate to ensure the stability of hinokitiol over time within the dosage form and to realize a synergistic effect in relation to the prevention, alleviation and treatment of oral diseases. DETAILED DESCRIPTION OF THE INVENTION

[0057] The present invention will be described in more detail below with reference to examples. These examples are provided to more specifically explain the present invention, and it will be obvious to those skilled in the art to which the present invention pertains that the scope of the present invention is not limited by these examples. [Example]

[0058] Production Example 1: Production of oral composition To evaluate the stability over time and oral efficacy of hinokitiol in a dosage form, toothpaste compositions were prepared as shown in Table 1 below.

[0059] [Table 1]

[0060] Experimental Example 1: Evaluation test of stability of content over time The toothpaste compositions in Table 1 were filled into toothpaste tubes and stored at 50° C. for 1 month. The hinokitiol content was analyzed immediately after production and after storage, and the residual hinokitiol rate (%) was calculated using the following formula.

[0061] Residual rate (%) = (Hinokitiol content after storage / Hinokitiol content immediately after production) x 100

[0062] The measurement results are shown in Table 2 below.

[0063] [Table 2]

[0064] Calcium pyrophosphate is an insoluble calcium salt that is usually used as an abrasive in toothpaste compositions. Experimental results showed that in Examples 1 to 5, in which water-soluble pyrophosphate was added, the residual rate of hinokitiol was 100%, confirming that the stability of hinokitiol over time within the dosage form was ensured. On the other hand, in Comparative Example 5, in which insoluble calcium pyrophosphate was added, the stability of hinokitiol over time within the dosage form was very low, similar to Comparative Example 2, in which no phosphate was added.

[0065] In the case of Comparative Example 4, in which monophosphate (sodium dihydrogen phosphate) was added instead of pyrophosphate, the residual rate of hinokitiol was higher than in Comparative Example 2, in which no phosphate was added, but it was confirmed that this was far below that of Examples 1 to 5.

[0066] Therefore, it is desirable that the oral composition of the present invention is substantially free of water-insoluble calcium pyrophosphate or monophosphate, but phosphates other than water-soluble pyrophosphates, such as water-insoluble pyrophosphates such as calcium pyrophosphate or water-soluble pyrophosphates, such as monophosphates, may be blended together with the water-soluble pyrophosphate, within a range in which the residual rate of hinokitiol can be maintained by adding water-soluble pyrophosphates, for example, within a range in which the residual rate is maintained at 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100%.

[0067] Experimental example 2: Antibacterial effect experiment The strain inhibitory effect was confirmed by a comparative antibacterial activity test using gram-positive bacteria Streptococcus mutans and gram-negative bacteria Streptococcus sanguis, which are typical bacteria that cause dental caries and periodontal disease. Examples 1 to 5 and Comparative Examples 1 to 3 were dissolved at a 10% concentration to prepare samples. 4.5 ml of medium was placed in each of the prepared test tubes, and 5 ml of the prepared sample at a 2% concentration was placed in the first test tube only, and then the samples were serially diluted two-fold. 100 μl of each strain was added to this dilution solution at 2×10 5 The strains were added to each test tube so that the concentration was CFU / ml, and after culturing for 16 hours or more under the optimal conditions for each strain as shown in Table 3 below, the minimum inhibitory concentration (MIC) at which no turbidity was observed was measured. The results are shown in Table 4 below.

[0068] [Table 3]

[0069] [Table 4]

[0070] As a result of the experiment, the toothpaste compositions of Comparative Example 1, which did not contain either hinokitiol or water-soluble pyrophosphate, Comparative Example 2, which contained only hinokitiol, and Comparative Example 3, which contained only water-soluble pyrophosphate, showed low antibacterial effects, while Examples 1 to 5, which contained both hinokitiol and water-soluble pyrophosphate, showed significantly increased antibacterial effects, confirming the synergistic effect of the combination of hinokitiol and water-soluble pyrophosphate.

[0071] Experimental Example 3: Inhibitory effect on gingivitis formation To confirm the inhibitory effect of the compositions of the Examples and Comparative Examples on gingivitis formation, 160 subjects with uniformly aligned teeth and no missing teeth were selected as experimental subjects. They were divided into groups of 20 and 30, with 40 subjects divided by gender and age group, ranging from 20 to 50 years old, in 10-year intervals. A detailed oral examination was then conducted to select 160 subjects. Clinical trials were then conducted on the therapeutic effects of gingivitis in groups of 20 subjects. Subjects were given oral prophylaxis three times a day, two hours after meals and before sleep, and the initial gingivitis index was scored. After using each toothpaste composition, oral examinations were conducted one week, one month, and three months later to assess the gingivitis index. The gingivitis index was measured by inserting a periodontal probe into the gingival sulcus and probing continuously around each tooth without applying force. After 30 seconds, bleeding was measured and scored according to the method shown in Table 5 below. The results of the measured inhibitory effect on gingivitis are shown in Table 6 below.

[0072] [Table 5]

[0073] [Table 6]

[0074] Experimental Example 4: Comparison of the degree of suppression of tooth sensitivity To compare the degree of tooth sensitivity suppression between the compositions of the Examples and Comparative Examples, 160 supporters aged 20 to 50 with sensitive teeth who agreed to participate in the experiment were selected as study subjects, and the experimental groups were divided into groups of 20 people each to conduct clinical experiments on the tooth sensitivity suppression effect. The total experimental period was two weeks.

[0075] The test was conducted by measuring the patient's response after applying temperature stimulation. Prior to the experiment, the sensitive areas of each patient's teeth were checked, and cold water of about 5°C was dripped onto the sensitive areas with a dropper and a rating was given. Each composition was then used three times a day for two weeks, and after two weeks, cold water of about 5°C was dripped onto the sensitive areas with a dropper and a rating was given. The criteria for rating the patient's response after stimulation were set as follows:

[0076] 0 points: No inconvenience whatsoever. 1 point: Slight inconvenience or pain. 2 points: Slightly stains. 3 points: Painful.

[0077] The reaction scores to the thermal stimulation after two weeks are shown in Table 7 below.

[0078] [Table 7]

[0079] Experimental example 5: Bad breath removal effect experiment To compare the effectiveness of oral halitosis, 160 caries-free men and women aged 20 to 50 were selected as study subjects. Experimental groups were divided into groups of 20 subjects each and a clinical study was conducted to evaluate the effectiveness of oral halitosis. Commercially available garlic powder was dispersed in water, left for 24 hours, and then diluted to a Halimeter reading of 700 ppb or higher. This diluted solution was used as the halitosis inducer. Subjects gargled with 15 ml of diluted garlic powder for 30 seconds, and after 1 minute, the level of halitosis was measured with the Halimeter. Then, subjects brushed their teeth for 30 seconds to 1 minute using toothpaste containing each experimental composition. After 1, 5, and 30 minutes of brushing, the level of halitosis was measured with the Halimeter to determine the duration of halitosis suppression. The results are shown in Table 8 below.

[0080] [Table 8]

[0081] Experimental Example 6: Tartar and plaque removal effect experiment In order to confirm the tartar and plaque removal effects of the compositions of the Examples and Comparative Examples, an experiment was conducted on 160 men and women aged 20 to 50 who had a lot of tartar. The experimental groups were divided into groups of 20 people each, and they were instructed to use a commercially available fluoride toothpaste for one week. At this time, the tartar index and plaque index were recorded and used as the initial index values. Each experimental composition was provided, and the subjects were familiarized with the same oral hygiene management method. After using the composition for three months, the tartar index (late tartar index) and plaque index (late plaque index) were evaluated, and the reduction rate was calculated using the following formula:

[0082] Tartar reduction rate (%) = {(initial tartar index - late tartar index) / initial tartar index} x 100 Plaque reduction rate (%) = {(initial plaque index - late plaque index) / initial plaque index} × 100 The results are shown in Table 9 below.

[0083] [Table 9]

[0084] From the above six experiments, it was confirmed that when hinokitiol is formulated in combination with water-soluble pyrophosphate, the stability of hinokitiol within the dosage form over time is ensured, and that pyrophosphate enhances the efficacy of hinokitiol on the oral cavity, creating a synergistic effect.

[0085] The toothpaste compositions of the comparative examples had no or only a slight effect on the oral cavity, while the toothpaste compositions of Examples 1 to 5 had superior oral effect compared to the toothpaste compositions of Comparative Examples 1 to 3.

[0086] For these reasons, it is believed that water-soluble pyrophosphate improves the stability of hinokitiol and improves the antibacterial, gum disease, toothache, bad breath, tartar and plaque removal effects of hinokitiol, making it an excellent composition for effectively maintaining and improving oral health.

Claims

1. An oral composition for improving the stability of hinokitiol or a salt thereof over time, comprising: (i) hinokitiol or a salt thereof; and (ii) a water-soluble pyrophosphate, The oral composition, wherein the water-soluble pyrophosphate is at least one selected from the group consisting of sodium pyrophosphate (Na 4 P 2 O 7 ) and sodium acid pyrophosphate (Na 2 H 2 P 2 O 7 ).

2. The oral composition according to claim 1, characterized in that the oral composition is for preventing, alleviating or treating oral diseases.

3. The oral composition according to claim 2, characterized in that the oral disease is one or more diseases selected from the group consisting of bad breath, sensitive teeth, caries, gingivitis, periodontal disease, oral mucosal ulcers, periapical disease, tartar, and plaque.

4. 2. The oral composition according to claim 1, wherein the content of hinokitiol or a salt thereof is 0.001 to 1% by weight based on the total weight of the composition.

5. 2. The oral composition according to claim 1, wherein the content of the water-soluble pyrophosphate is 0.01 to 10% by weight based on the total weight of the composition.

6. 2. The oral composition according to claim 1, wherein the composition has an antibacterial effect against one or more microorganisms selected from the group consisting of microorganisms of the genus Streptococcus and Porphyromonas.

7. An oral product comprising the oral composition of any one of claims 1 to 6.

8. The oral product according to claim 7, characterized in that the oral product is one or more selected from the group consisting of toothpaste, gargle, gum, mouth spray, oral ointment, mouthwash and mouth cleanser.

Images